RJ 4287
Alternative Names: RJ-4287Latest Information Update: 25 Aug 2023
At a glance
- Originator Nanjing Olymus Medical Technology
- Developer Nanjing Olymus Medical Technology; Nanjing Ruijie Pharma
- Class Hepatoprotectants
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 04 Jul 2023 Pharmacokinetic, Pharmacodynamic and adverse events data from preclinical trial in Non-alcoholic steatohepatitis released by Ruijie Pharmaceuticals, prior to July 2023 (Ruijie Pharmaceuticals wesite, July 2023)
- 13 Jun 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in China (PO) (NCT05921006)
- 06 Jun 2023 Pharmacodynamic and pharmacokinetic data from preclinical trial in Non-alcoholic steatohepatitis released by Ennovation Ventures